Peptidomimetics Inspired by α-Synuclein or Its Chaperone αB-Crystallin Differentially Modulate α-Synuclein...

Area of Science:

• Neuroscience
• Biochemistry
• Drug Discovery

Background:

• Alpha-Synuclein (αSyn) protein aggregation in neurons causes synucleinopathies like Parkinson's disease.
• Pathological αSyn forms toxic oligomers and fibrils, leading to neuronal death.
• Currently, no treatments exist to prevent fatal synucleinopathies.

Purpose of the Study:

• To design and evaluate small peptidomimetics that inhibit αSyn aggregation.
• To explore the relationship between peptidomimetic structure, sequence, and their effect on αSyn aggregation.
• To develop novel therapeutic strategies for neurodegenerative diseases characterized by protein aggregation.

Main Methods:

• Designed peptidomimetics inspired by αSyn aggregates and the chaperone protein αB-Crystallin.
• Utilized in vitro and cellular assays to assess the compounds' impact on αSyn aggregation.
• Investigated the correlation between peptidomimetic characteristics and their anti-aggregation activity.

Main Results:

• One αB-Crystallin-based peptidomimetic effectively interfered with αSyn folding and aggregation.
• The compound reduced the formation of toxic αSyn oligomers.
• The study demonstrated the promotion of off-pathway aggregation by the peptidomimetic.

Conclusions:

• Physiological chaperone proteins can be mimicked by small peptide derivatives.
• This approach provides a new strategy for designing inhibitors of amyloid protein aggregation.
• The findings pave the way for potential treatments for neurodegenerative and systemic amyloid diseases.